Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension

摘要: Pulmonary hypertension in the neonate is associated with multiple underlying problems such as respiratory distress syndrome, meconium aspiration congenital diaphragmatic hernia, bronchopulmonary dysplasia, sepsis, or heart disease. Because of heterogeneous group disorders, therapeutic approach and response often depends on In many these conditions, there evidence that cyclic nucleotide signaling specifically phosphodiesterases (PDEs) are disrupted. PDE inhibitors represent an emerging class pulmonary vasodilators adults. Studies now under way to evaluate utility, efficacy, safety therapies infants hypertension.